FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

NCT05432193 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

20

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision

Conditions

Pancreatic Ductal Adenocarcinoma
Colorectal Cancer
Esophageal Cancer
Melanoma (Skin)
Soft Tissue Sarcoma
Head and Neck Squamous Cell Carcinoma
Cholangiocarcinoma

Interventions

DRUG: [Ga-68]-PNT6555
DRUG: [Lu-177]-PNT6555

Sponsor

POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company